Lyra Therapeutics, Inc. (LYRA) 株式分析

企業概要

Lyra Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to the research, development, and commercialization of novel anti-inflammatory therapeutic modalities specifically designed for the treatment of chronic rhinosinusitis. This specialized focus places the enterprise squarely within the Healthcare sector and the Biotechnology industry, where capital is typically allocated to entities capable of advancing candidates through rigorous clinical trial phases before seeking regulatory approval. The company currently maintains a market capitalization of 870,402 米ドル (米ドル換算), while its trailing twelve-month revenue stands at 398,000 米ドル, and the number of employees is not publicly disclosed in available data. These financial metrics collectively indicate that the company operates with a very small market capitalization relative to its revenue base, suggesting it is a micro-cap entity with limited scale and high sensitivity to market fluctuations. The substantial discrepancy between the market cap and the annual revenue figure highlights the speculative nature of clinical-stage biotechnology firms, where valuation is often driven by future potential rather than current cash flow generation.

財務健全性

Lyra Therapeutics reported a trailing twelve-month revenue of 398,000 米ドル against a net income of -28,919,000 米ドル and an EBITDA of -29,094,000 米ドル. The significant negative gap between the modest revenue and the substantial net loss reveals a cost structure dominated by high research and development expenditures and operational overheads typical of pre-commercialization biotechnology companies. The free cash flow for the period was -17,529,624 米ドル, which indicates that the company is currently burning cash to fund its operations and development pipeline rather than generating liquidity from its core business activities. This negative free cash flow flow underscores the company's reliance on external capital sources, such as equity financing or debt issuance, to maintain financial solvency until product milestones are achieved. The gross margin is reported at -152.8%, the operating margin at -98,728.6%, and the profit margin at 0.0%, all of which reflect the heavy investment phase and lack of profitability inherent in clinical-stage ventures. In terms of balance sheet composition, the company holds 15.89M 米ドル in cash while carrying 30.26M 米ドル in debt, resulting in a debt-to-equity ratio that is not applicable due to the company's financial position. The current ratio is 1.71, which suggests that the company possesses 1.71 times more current assets than current liabilities, indicating a reasonable level of short-term liquidity to meet its immediate obligations. However, the return on equity is -6,595.0% and the return on assets is -36.1%, metrics that reveal that management has not yet generated positive returns on shareholder capital or the asset base, reflecting the early-stage nature of the enterprise.

バリュエーション評価

The trailing twelve-month P/E ratio is not applicable, while the forward P/E is listed at -0.50, a disparity that implies the market is not pricing in near-term earnings recovery but rather focusing on other valuation drivers common in loss-making biotech firms. The price-to-book ratio stands at -0.19, which indicates that the stock trades below its book value, a situation often seen in companies with significant intangible assets like intellectual property that are not fully captured on the balance sheet or where book value is distorted by accumulated deficits. Additionally, the price-to-sales ratio is 2.19 and the EV/EBITDA is -0.53, suggesting that the market values the company based on its revenue potential and sales pipeline rather than its earnings power or enterprise value multiples. The stock has exhibited extreme volatility, trading with a 52-week high of 37.50 米ドル and a 52-week low of 0.31 米ドル, meaning the current trading price sits significantly closer to the bottom of this historical range. The beta value is 0.30, which indicates that the stock's price movements are less volatile than the broader market, suggesting lower systemic risk despite the company's high risk profile due to its clinical-stage status.

Growth & Income

Lyra Therapeutics experienced a year-over-year revenue decline of -96.7%, while the earnings growth rate is not applicable due to the lack of profitability. The negative revenue growth rate indicates a contraction in sales, which is typical for companies transitioning from R&D focus to commercialization or facing market access challenges, whereas the non-applicable earnings growth further emphasizes the absence of a consistent profit trajectory. As the company does not pay dividends, with a dividend yield of not applicable and a payout ratio of 0.0%, it retains all available earnings and cash flow to reinvest into its research and development efforts rather than distributing income to shareholders. Consequently, the overall growth and income profile is characterized by negative revenue trends and zero dividend income, reflecting a strategy entirely focused on capitalizing on future clinical successes rather than providing current financial returns.